1. Home
  2. AVD vs CRDF Comparison

AVD vs CRDF Comparison

Compare AVD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Vanguard Corporation ($0.10 Par Value)

AVD

American Vanguard Corporation ($0.10 Par Value)

N/A

Current Price

$2.20

Market Cap

72.4M

Sector

Industrials

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.95

Market Cap

86.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVD
CRDF
Founded
1969
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
86.8M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
AVD
CRDF
Price
$2.20
$0.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$9.63
AVG Volume (30 Days)
295.1K
740.8K
Earning Date
03-16-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
27.37
EPS
N/A
N/A
Revenue
$515,114,000.00
$365,993.00
Revenue This Year
$8.82
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$2.03
$0.76
52 Week High
$5.92
$3.31

Technical Indicators

Market Signals
Indicator
AVD
CRDF
Relative Strength Index (RSI) 44.36 49.88
Support Level $2.03 $0.87
Resistance Level $2.67 $1.13
Average True Range (ATR) 0.16 0.07
MACD 0.01 0.02
Stochastic Oscillator 47.06 42.97

Price Performance

Historical Comparison
AVD
CRDF

About AVD American Vanguard Corporation ($0.10 Par Value)

American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: